The Bristol-Myers Squibb/Celgene merger has started 2019 with a bang in both healthcare and on Wall Street. A good hint as to what happens next starts during JP Morgan’s 37th Annual Healthcare Conference and the debate over the winners and losers for patients, payers and investors begins.
After Bristol-Myers Squibb Buys Celgene What’s Next? JP Morgan’s Conference Will Answer That
